Transplacentally transferred maternal-infant antibodies to dengue virus.
Antibodies of all four dengue virus serotypes were detected by hemagglutination inhibition (HI) in 97% of 2,000 infants' cord sera at the time of delivery. In comparison with 250 mother-infant's paired sera, we found that 53% of the infants' serum HI titers were higher than those of the mother's. The mother/infant IgG subclasses 1, 2, 3, and 4 titers were 53.1/87.0, 8.4/11.7, 0.14/0.11, and 1.1/1.0 mg/dL, respectively. In 18 months of follow-up of 100 infants studied, we observed that antibody to dengue virus disappeared in 3% by two months of age, in 19% by four months of age, in 72% by six months of age, in 99% by nine months of age, and in 100% by 12 months of age, with a half-life of 41 days. We conclude that the antibodies to dengue virus disappeared in the first year of life. We suggest that the most appropriate age for vaccination with a live-attenuated dengue vaccine in an endemic area is one year of age.
D000293:Adolescent; D000328:Adult; D000914:Antibodies, Viral / Q000097:blood / Q000276:immunology*; D015153:Blotting, Western; D003716:Dengue Virus / Q000145:classification / Q000276:immunology*; D005260:Female; D005312:Fetal Blood / Q000821:virology; D006385:Hemagglutination Inhibition Tests; D006801:Humans; D007112:Immunity, Maternally-Acquired; D007115:Immunization Schedule; D007231:Infant, Newborn; D008875:Middle Aged; D011247:Pregnancy; D019595:Severe Dengue / Q000276:immunology* / Q000517:prevention & control; D014765:Viral Vaccines / Q000008:administration & dosage
D000914:Antibodies, Viral; D014765:Viral Vaccines